NovoCure Ltd

NovoCure Ltd

NVCR

Get informed when a big investor buys or sells

+ Follow
Market Cap$1.94B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
NovoCure LtdNovoCure Ltd-12.8--44%2.70.7
$37.50

Target Price by Analysts

130.8% upsideNovoCure Target Price DetailsTarget Price
$-7.68

Current Fair Value

147.3% downside

Overvalued by 147.3% based on the discounted cash flow analysis.

Share Statistics

Market cap$1.94 Billion
Enterprise Value$2.08 Billion
Dividend Yield$- (-)
Earnings per Share$-1.22
Beta1.01
Outstanding Shares116,012,397

Return

Return on Equity-43.94%ROE
Return on Assets-18.68%
Return on Invested Capital-26.97%

Valuation & Multiples

P/E Ratio-12.84P/E Ratio
PEG21.05PEG
Price to Sales2.71Price to Sales
Price to Book Ratio8.13Price to Book Ratio
Enterprise Value to Revenue2.98
Enterprise Value to EBIT-13.44
Enterprise Value to Net Income-15
Total Debt to Enterprise0.11
Debt to Equity0.69Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
July 23, 2026
EPS Estimate
$-0.33
Average shareholder expectation
Revenue Estimate
$172.44 M
Average shareholder expectation

Next Earnings Call

Expected Date
October 29, 2026
EPS Estimate
$-0.24
Average shareholder expectation
Revenue Estimate
$182.28 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.1875 55.68%
Total Calls763,900 17.94%
Total Puts143,200 79.33%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %90.13% 3.50%
Total Invested$1.59B 47.48%
Investors Holding231 1.00%

ESG Score

No data

About NovoCure Ltd

CEO: Asaf Danziger